StockNews.com Begins Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR)
StockNews.com initiated coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR – Free Report) in a research note published on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock. Separately, Citigroup cut their price target on shares of Eiger BioPharmaceuticals from $4.00 to $3.00 and set a buy rating on the stock in […]
More Stories
New Mexico Oil and Gas Lease Sale Nets More Than $58 Million: DOI
By Naveen Athrappully The Bureau of Land Management (BLM) New Mexico State Office has generated over $58.26 million in revenues...
US Imposing 20.56 Percent Anti-Dumping Duties on Canadian Softwood
By The Canadian Press British Columbia lumber organizations are condemning the decision by the U.S. Commerce Department to raise anti-dumping...
California Utility Company Offers Direct Compensation to Victims of Eaton Fire Amid Lawsuits, Investigation
By Kimberly Hayek Southern California Edison (SCE) is offering to directly pay victims of the Eaton Fire, the company said...
Miami: Messi ‘extremely upset’ with MLS over ‘draconian’ ban
By Lizzy Becherano Inter Miami co-owner Jorge Mas said Lionel Messi is “extremely upset” after being issued a one-game suspension by Major League Soccer for...
First 100 Illegal Immigrants Deported from ‘Alligator Alcatraz’ as DHS Starts Flights
By T.J. Muscaro BIG CYPRESS NATIONAL PRESERVE, Fla.—The first 100 deportations of illegal immigrants held at Alligator Alcatraz have occurred,...
FCC Approves Paramount’s $8 Billion Merger Deal With Skydance
By Jacob Burg The Trump administration approved CBS parent company Paramount Global’s $8 billion merger with Skydance, Federal Communications Commission...